Aytu BioPharma (AYTU) Expected to Announce Quarterly Earnings on Wednesday

Aytu BioPharma (NASDAQ:AYTU) is projected to issue its Q3 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.4433) per share and revenue of $12.0530 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The business had revenue of $15.17 million for the quarter, compared to analyst estimates of $12.17 million. On average, analysts expect Aytu BioPharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Aytu BioPharma Stock Up 0.8%

Shares of NASDAQ AYTU opened at $2.57 on Wednesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.03 and a current ratio of 1.16. Aytu BioPharma has a 1 year low of $1.20 and a 1 year high of $3.07. The stock’s 50-day simple moving average is $2.58 and its 200-day simple moving average is $2.44. The firm has a market cap of $27.58 million, a price-to-earnings ratio of -0.67 and a beta of 0.28.

Institutional Investors Weigh In On Aytu BioPharma

Several institutional investors and hedge funds have recently made changes to their positions in AYTU. Persistent Asset Partners Ltd raised its holdings in shares of Aytu BioPharma by 27.2% during the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock worth $206,000 after purchasing an additional 16,963 shares during the period. Rothschild Wealth LLC bought a new stake in Aytu BioPharma in the fourth quarter valued at $52,000. XTX Topco Ltd acquired a new position in shares of Aytu BioPharma during the fourth quarter valued at $67,000. DRW Securities LLC bought a new position in shares of Aytu BioPharma during the fourth quarter worth about $76,000. Finally, Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma during the third quarter worth about $58,000. 33.49% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AYTU. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Wednesday, April 8th. Zacks Research lowered Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 31st. Finally, Wall Street Zen upgraded Aytu BioPharma to a “hold” rating in a research note on Saturday, February 7th. Three equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.33.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.